<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20210">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02843789</url>
  </required_header>
  <id_info>
    <org_study_id>P/2011/118</org_study_id>
    <nct_id>NCT02843789</nct_id>
  </id_info>
  <brief_title>Evolution of Adipokines and Body Composition in Rheumatoid Arthritis Patients Receiving Tocilizumab Therapy</brief_title>
  <acronym>ADIPRAT</acronym>
  <official_title>Evolution of Adipokines and Body Composition in Rheumatoid Arthritis Patients Receiving Tocilizumab Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to analyze the variation of adiponectinemia and its molecular forms
      in RA patients receiving tocilizumab therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with cardiovascular
      morbidity. Tocilizumab (TCZ), a monoclonal antibody against the interleukin-6 receptor is an
      effective new biotherapy for the treatment of RA. This treatment is associated with
      increased LDL and HDL-cholesterol lipid parameters. Adipokines are adipose tissue-specific
      secreted molecules, which have many functions such as regulation of appetite, blood glucose
      or immune response. Among the adipokines, adiponectin exerts beneficial effects on the
      cardiovascular system. Patients with RA also exhibit body composition changes, including an
      increase in abdominal visceral fat. The impact of tocilizumab therapy in RA patients on
      adipokines and body composition is not known.

      This project aims to explore the evolution of circulating adiponectin and other adipokines
      during tocilizumab therapy in RA. Body composition and its variations under tocilizumab
      therapy will also be analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum total adiponectin (ng/ml)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum high-molecular weight adiponectin (ng/ml)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>Adiponectin evaluation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients evaluated for serum adiponectin level and for body composition before each infusion of Tocilizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <arm_group_label>Adiponectin evaluation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a diagnosis of RA and requiring Tocilizumab therapy

          -  Subject has provided written informed consent

        Exclusion Criteria:

          -  Corticosteroid therapy (10 mg/day of prednisone or equivalent)

          -  Pregnant or lactating women

          -  Uncontrolled type 1 or type 2 diabetes

          -  Uncontrolled dyslipidemia

          -  Elevated transaminases (&gt; three times higher than the normal range)

          -  History of diverticulitis or intestinal perforation

          -  Tocilizumab contraindications: Severe or active infections, Hypersensitivity to the
             active substance or to any of the excipients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Toussirot, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Besançon, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric Toussirot, Professor</last_name>
    <email>etoussirot@chu-besancon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elise Robert</last_name>
    <email>e1robert@chu-besancon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>February 14, 2017</lastchanged_date>
  <firstreceived_date>July 19, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adipokines</keyword>
  <keyword>Tocilizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
